DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery
Status unconfirmed · Phase 4
Conditions studied: Retinopathy, Diabetic
In brief
The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.
Key facts
- Study ID
- NCT04362241
- Run by
- Ophthalmic Consultants of the Capital Region
- People needed
- 30
- Starts
- 2020-08-07
- Expected to finish
- 2022-03-01
- Last updated by the study team
- 2020-08-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Binocular
- >18 years old
- Any level of Background Diabetic Retinopathy
- Cataract surgery candidate in each eye
- Pre-operative OCT and Fluorescein Angiography showing no Macular edema
You may not qualify if…
- Participant cannot complete second eye operation within 60 days of the first cataract surgery
- Maintains regular use of systemic or ocular steroids at time of enrollment
- Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment
- Anterior chamber cells present at time of enrollment
- Recent febrile illness that precludes or delays participation for 90 days
- Pregnancy or lactation
- Known allergy to dexamethasone
- Known allergy to prednisolone
- Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema.
- Posterior capsule rupture or other intraoperative complication in first eye operated on
- Amblyopia
- Anti-VEGF injections within 6 months prior to surgery day.
- Intraocular steroid injection within 6 months prior to surgery day.
- Intraocular surgeries within 6 months prior to surgery day.
- Laser photocoagulation within 30 days prior to surgery day.
- Any type of eye inflammation
- Any punctum inflammation or dacryocystitis
Where it is running
- Ophthalmic Consultants of the Capital Region — Troy, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.